Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Hayman

Showing results (321-330 of 446) with videos related to

Pageof 45
Sort By:
American Journal of Hematology|July 8, 2023
Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myelomaSaurabh Zanwar, Matthew Ho, Yi Lin, et al.
Blood|April 12, 2012
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosisAngela Dispenzieri, Francis Buadi, Kristina Laumann, et al.
American Journal of Hematology|June 2, 2011
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trialShaji K Kumar, Martha Q Lacy, Suzanne R Hayman, et al.
American Journal of Hematology|April 4, 2017
Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemiaSurbhi Sidana, S Vincent Rajkumar, Angela Dispenzieri, et al.
American Journal of Hematology|April 17, 2018
Time to plateau as a predictor of survival in newly diagnosed multiple myelomaPatrick W Mellors, Moritz Binder, Francis K Buadi, et al.
Mayo Clinic Proceedings|October 3, 2008
Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiativeMorie A Gertz, Stephen M Ansell, David Dingli, et al.
Mayo Clinic Proceedings|February 3, 2009
Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative componentJohn A Lust, Martha Q Lacy, Steven R Zeldenrust, et al.
Blood Cancer Journal|December 12, 2023
Muscle and fat composition in patients with newly diagnosed multiple myelomaNadine H Abdallah, Hiroki Nagayama, Naoki Takahashi, et al.
Blood Advances|August 21, 2023
Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapyCharalampos Charalampous, Utkarsh Goel, Prashant Kapoor, et al.
American Journal of Hematology|September 30, 2017
Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL)Nidhi Tandon, Surbhi Sidana, Angela Dispenzieri, et al.
Pageof 45

Showing results (321-330 of 446) with videos related to

Sort By:
Pageof 45
American Journal of Hematology|July 8, 2023
Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myelomaSaurabh Zanwar, Matthew Ho, Yi Lin, et al.
Blood|April 12, 2012
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosisAngela Dispenzieri, Francis Buadi, Kristina Laumann, et al.
American Journal of Hematology|June 2, 2011
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trialShaji K Kumar, Martha Q Lacy, Suzanne R Hayman, et al.
American Journal of Hematology|April 4, 2017
Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemiaSurbhi Sidana, S Vincent Rajkumar, Angela Dispenzieri, et al.
American Journal of Hematology|April 17, 2018
Time to plateau as a predictor of survival in newly diagnosed multiple myelomaPatrick W Mellors, Moritz Binder, Francis K Buadi, et al.
Mayo Clinic Proceedings|October 3, 2008
Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiativeMorie A Gertz, Stephen M Ansell, David Dingli, et al.
Mayo Clinic Proceedings|February 3, 2009
Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative componentJohn A Lust, Martha Q Lacy, Steven R Zeldenrust, et al.
Blood Cancer Journal|December 12, 2023
Muscle and fat composition in patients with newly diagnosed multiple myelomaNadine H Abdallah, Hiroki Nagayama, Naoki Takahashi, et al.
Blood Advances|August 21, 2023
Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapyCharalampos Charalampous, Utkarsh Goel, Prashant Kapoor, et al.
American Journal of Hematology|September 30, 2017
Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL)Nidhi Tandon, Surbhi Sidana, Angela Dispenzieri, et al.
Pageof 45